|
|
|
04.11.26 - 15:31
|
CFO-Wechsel bei Novo Nordisk (Börsen-Zeitung)
|
|
|
Novo Nordisk bekommt einen neuen Finanzchef: Karsten Munk Knudsen verlässt den dänischen Pharmakonzern nach 27 Jahren zum Jahresende. Nachfolger wird Luigi La Corte, bislang Finanzvorstand beim Dermatologie-Konzern Galderma....
|
|
|
|
|
|
|
|
|
|
|
02.11.26 - 18:03
|
Galderma Announces Proposed Board Appointments and Chief Financial Officer Transition (Business Wire)
|
|
|
The Company will hold an Extraordinary General Meeting on December 3, 2026 to further reinforce its Board of Directors
Ad hoc announcement pursuant to Art. 53 LRZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced proposed changes to its Board of Directors, aimed at further strengthening its governance and supporting its long-term growth. The company also announced that Luigi La Corte, Chief Financial Officer (CFO), has decided to leave Galderma to pursue a significant new opportunity.
Luigi La Corte will continue to fulfil his responsibilities as CFO during the transition period, supporting business continuity and a smooth handover. The company will communicate further details regarding succession arrangements and the transition timeline in due course.
The Board of Directors is proposing the election of Rosalind Brewer and Petra Rumpf as new Board members. Both candidates bring extensive leadership and governance experience, alongside...
|
|
|
27.10.26 - 07:36
|
Life Sciences: Wie KI das Wachstum im Healthcare-Sektor beschleunigt (SchweizerAktien)
|
|
|
Der Hauptprofiteur der Gewinnmitnahmen im Tech-Sektor ist das Bio-Pharma Universum. An des SIX glänzen Spezialisten-Aktien wie Galderma und SKAN Group. Die Aktie von Moderna ist mit über 650% Kursanstieg im […]
Der Beitrag Life Sciences: Wie KI das Wachstum im Healthcare-Sektor beschleunigt erschien zuerst auf schweizeraktien.net....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
22.10.26 - 07:54
|
Galderma hebt Guidance für 2026 erneut an (Moneycab)
|
|
|
Galderma ist im dritten Quartal über alle Sparten und Regionen hinweg dynamisch gewachsen. Angesichts der anhaltend starken Geschäftsentwicklung erhöht die Hautpflege-Spezialistin ihre Jahresprognose zum zweiten Mal....
|
|
|
22.10.26 - 07:24
|
Galderma hebt Guidance für 2026 erneut an (Cash)
|
|
|
Dermatologiespezialist - Galderma ist im dritten Quartal über alle Sparten und Regionen hinweg dynamisch gewachsen. Angesichts der anhaltend starken Geschäftsentwicklung erhöht die Hautpflege-Spezialistin ihre Jahresprognose zum zweiten Mal....
|
|
|
22.10.26 - 07:06
|
Galderma Delivers Net Sales of 4.765 B USD in the First Nine Months, Up 25.1% at Constant Currency Year-on-Year, and Raises Full-Year Net Sales Guidance (Business Wire)
|
|
|
Ad hoc announcement pursuant to Art. 53 LRZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first nine months of 2026.
Record net sales of 4.765 billion USD for the first nine months of 2026, representing 25.1% year-on-year growth at constant currency1, predominantly driven by volume and complemented by favorable mix.
Broad-based double-digit growth across geographies and product categories, reflecting strong execution of Galderma's proven integrated dermatology strategy, with stand-out performance in Therapeutic Dermatology, across both Nemluvio and the mature portfolio, as well as in Dermatological Skincare and Neuromodulators.
Continued market outperformance across all three product categories, with net sales growth year-on-year at constant currency of 13.2% in Injectable Aesthetics, 16.2% in Dermatological Skincare, and 64.4% in Therapeutic Dermatology (with Nemluvio net sales of 735 million USD).
...
|
|